Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

DCMAN About the GCDX web site..It did recently add "Recent News" under "About Us"...Remember William was going to trademark the term "The Lung Cancer Test"

Here is the result

2014-08-20 ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND

http://trademarks.justia.com/860/79/the-lung-cancer-86079607.html

Now on the news release he has a Tm after the term..The Lung Cancer Test for Early Detection™ That is baloney..I checked the trademark applications and came up empty..GCDX has not filed a trademark for that mark as the news release has suggested..The same thing when Radient and Provista were collaborating..They placed a TM after LC Sentinel..There has never been an application for the trademark "LC Sentinel"..Link is below...

http://www.businesswire.com/news/home/20140827006035/en/Global-Cancer-Diagnostics-Announces-Start-Final-Validation#.VB0C


Global Cancer Diagnostics Announces Start of Final Validation Study for Its New Blood Test for the Early Detection of Lung Cancer
August 27, 2014 12:26 PM Eastern Daylight Time

PHOENIX--(BUSINESS WIRE)--Global Cancer Diagnostics Inc. today announced the start of the final validation study of its new blood test for early detection of lung cancer. The study will complete the requisite analyses and data evaluation needed to validate the test and introduce it to the market. Global Cancer Diagnostics (GCDx) plans to offer this new test on a nationwide basis.

“By industry standards the studies have been very successful and will serve as the cornerstone to GCDx’s introduction of this new lung cancer detection assay to market”

Clinical Studies to date demonstrated that The Lung Cancer Test for Early Detection™ successfully detected Stages 1 and 2 lung cancer with a high degree of accuracy in both men and women. The results generated in this final validation study are fully expected to be consistent with previous findings and produce positive clinical performance.

“By industry standards the studies have been very successful and will serve as the cornerstone to GCDx’s introduction of this new lung cancer detection assay to market,” shared Global Cancer CEO William Gartner. “GCDx intends to introduce The Lung Cancer Test for Early Detection™ out of its CLIA Laboratory immediately upon successful completion of this final study.” This validation study will allow the test to be marketed while the company seeks FDA clearance.

The Lung Cancer Test for Early Detection™ is intended for use in the high-risk lung cancer patient population which includes current and former smokers. While the Company intends to offer the test through standard clinical channels that include physicians, medical clinics and hospitals, a program has been developed to offer the test direct to consumers (DTC) through its website in the 26 states allowing DTC diagnostic sales. The company expects to seek FDA registration for The Lung Cancer Test for Early Detection™ in early 2015.

“We expect the test to be made available for a price that is easily within reach of the subject population, even those without medical insurance,” added Global Cancer Diagnostics’ VP of Marketing, Don Roberton.

“We believe this test will change the way that lung cancer is detected and can potentially save thousands of lives,” said Gartner.

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$


News | October 14, 2010
Radient Pharmaceuticals And Provista Life Sciences Announce New Blood Test For Lung Cancer
LC04.jpg

Tustin, CA (Marketwire) - Provista Life Sciences and Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the validation study results of a blood test for early detection of lung cancer and Provista's plans to broadly introduce this new test to market.

The study completed the requisite analyses and data evaluation needed to validate Provista's test, based on Radient Pharmaceutical Corporation's antigens for fibrinogen degradation products (FDP), successfully detects lung cancer with a high degree of accuracy. The study included men and women between 20-76 years of age. The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97. By industry standards the study proved very successful and will serve as the cornerstone to Provista's efforts to introduce a new lung cancer detection assay branded LC Sentinel™ to market. Provista intends to introduce LC Sentinel™ as a CLIA Laboratory Developed Test (LDT) for use in high-risk lung cancer patient populations in the U.S. by the end of the fourth quarter 2010 through its standard clinical channels that include physicians, medical clinics and hospitals. The company expects to seek FDA registration for LC Sentinel™ in 2011.


News | October 14, 2010
Radient Pharmaceuticals And Provista Life Sciences Announce New Blood Test For Lung Cancer
LC04.jpg

Tustin, CA (Marketwire) - Provista Life Sciences and Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the validation study results of a blood test for early detection of lung cancer and Provista's plans to broadly introduce this new test to market.

The study completed the requisite analyses and data evaluation needed to validate Provista's test, based on Radient Pharmaceutical Corporation's antigens for fibrinogen degradation products (FDP), successfully detects lung cancer with a high degree of accuracy. The study included men and women between 20-76 years of age. The data generated in this final study proved consistent with previous findings and produced positive clinical performance marks of 87% sensitivity; 95% specificity; and an ROC Accuracy of 0.97. By industry standards the study proved very successful and will serve as the cornerstone to Provista's efforts to introduce a new lung cancer detection assay branded LC Sentinel™ to market. Provista intends to introduce LC Sentinel™ as a CLIA Laboratory Developed Test (LDT) for use in high-risk lung cancer patient populations in the U.S. by the end of the fourth quarter 2010 through its standard clinical channels that include physicians, medical clinics and hospitals. The company expects to seek FDA registration for LC Sentinel™ in 2011.